A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (NCT06747351)
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
🩺 Plain-English Summary (8th-Grade Level)
The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP. The participants who are already receiving intravenous immunoglobulin G (IGIV), conventional subcutaneous intravenous immunoglobulin G (cIGSC), or HYQVIA will be treated with the same dose equivalent as their prior IG treatment with HYQVIA for 20 weeks followed by TAK-881 for 24 weeks. Participants will need to visit the clinic every 3 or 4 weeks until they enter the extension phase. In the extension phase, home infusions are allowed, and visits will occur between every 12 weeks and 24 weeks.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Neurology — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- HonorHealth Neurology — Scottsdale, Arizona
- Stanford Neuroscience Health Center — Palo Alto, California
- Yale University School of Medicine — New Haven, Connecticut
- Neurology Associates — Maitland, Florida
- Knight Neurology — Rockledge, Florida
- The Washington University — St Louis, Missouri
- NYU Langone Health — New York, New York
- University of North Carolina (UNC) — Chapel Hill, North Carolina
- Duke University Hospital — Durham, North Carolina
- Raleigh Neurology Associates — Raleigh, North Carolina
- Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Oregon Health & Science University (OHSU) - Nephrology and Hypertension Clinic - Marquam Hill — Portland, Oregon
- Neurology Rare Disease Center — Denton, Texas
- The University of Vermont Medical Center — Burlington, Vermont
- BCN Research, LLC — Greenfield, Wisconsin
- INECO — Rosario, Santa Fe Province
- Instituto Argentino de Investigacion Neurologica (IADIN) — Buenos Aires,
- Fakultni nemocnice Hradec Kralove — Hradec Králové,
- Copenhagen University Hospital — Copenhagen, Capital Region
- Aarhus Universitetshospital — Aarhus, Central Jutland
- Universitätsklinikum Mannheim GmbH — Mannheim, Baden-Wurttemberg
- University of Ulm — Ulm, Baden-Wurttemberg
- Universitaetsklinikum Giessen und Marburg GmbH Standort Marburg — Marburg, Hesse
- Medizinische Hochschule Hannover — Hanover, Lower Saxony
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Explore by condition: All Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.